Rapid symptomatic improvement with etrasimod in ulcerative colitis: a post-hoc analysis of the ELEVATE UC program
Inflammatory Bowel Diseases · 2026
DOI: 10.1093/ibd/izaf333 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Inflammatory Bowel Diseases, 2026. Verfasst von Marla C Dubinsky und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine and Pediatrics, Icahn School of Medicine at Mount Sinai, New York, NY, United States. Hauptthemen laut MEDLINE: Colitis, Ulcerative, Sphingosine 1 Phosphate Receptor Modulators. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 23 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Pfizer Inc..
Abstract (Originalsprache)
Introduction
Rapid symptom relief is an important consideration for patients with ulcerative colitis (UC) experiencing a flare. Etrasimod is an oral, once-daily, selective sphingosine 1-phosphate1,4,5 receptor modulator for the treatment of moderately to severely active UC. We evaluated patient-reported symptomatic improvement from patients in the ELEVATE UC program.
Methods
This study was a post-hoc analysis of pooled daily e-diary data from patients with moderately to severely active UC receiving etrasimod or placebo in the phase III ELEVATE UC 52 and ELEVATE UC 12 trials. During the 12-week induction periods, patients self-reported stool frequency and rectal bleeding on days 1-28. Daily symptomatic response and symptomatic remission were calculated (partial modified Mayo Score).
Results
Overall, 787 patients (527 receiving etrasimod, 260 placebo) were included in the analysis. Etrasimod-treated patients had statistically significantly higher rates of symptomatic response and symptomatic remission during the first 28 days of therapy, with adjusted differences (95% CIs) reaching statistical significance from day 2 (5.6% [0.8-10.3], P = .022) to day 11 (4.7% [0.4-9.0], P = .034), respectively. In patients naïve to biologic/Janus kinase inhibitor therapy, symptomatic response was statistically significantly improved with etrasimod vs placebo from day 3 (8.9% [2.3-15.5], P = .008). Symptomatic improvement rates were similar with and without concomitant corticosteroid use.
Conclusions
In this post-hoc analysis, improvements in UC symptoms occurred in patients receiving etrasimod vs placebo from as early as day 2. These findings indicate a rapid onset of symptomatic effect with etrasimod treatment for moderately to severely active UC. ClinicalTrials.gov numbers NCT03945188, NCT03996369.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medicine and Pediatrics, Icahn School of Medicine at Mount Sinai, New York, NY, United States.
- Gastroenterology Unit, Hospital Universitario de La Princesa, Instituto de Investigación Sanitaria Princesa (IIS-Princesa), Universidad Autónoma de Madrid (UAM), Centro de Investigación Biomédica en Red de Enfermedades…
- IBD Unit, Guy's and St Thomas' National Health Service Foundation Trust, London, United Kingdom.
- HTA, Value & Evidence, Pfizer Inc, New York, NY, United States.
- Global Medical Affairs, Pfizer Inc, New York, NY, United States.
- Global Medical Affairs, Pfizer Inc, Collegeville, PA, United States.
ORCID-Profile: Marla C Dubinsky, María Chaparro, Peter M Irving, Joana Torres, Remo Panaccione
Förderung
- Pfizer Inc.
Zitieren
APA
Dubinsky, M. C., Chaparro, M., Irving, P. M., Hur, P., Sidhu, S., Woolcott, J. C., Wang, W., Goetsch, M., Torres, J., & Panaccione, R. (2026). Rapid symptomatic improvement with etrasimod in ulcerative colitis: a post-hoc analysis of the ELEVATE UC program. Inflammatory Bowel Diseases. https://doi.org/10.1093/ibd/izaf333
Vancouver
Dubinsky MC, Chaparro M, Irving PM, Hur P, Sidhu S, Woolcott JC, et al. Rapid symptomatic improvement with etrasimod in ulcerative colitis: a post-hoc analysis of the ELEVATE UC program. Inflammatory Bowel Diseases. 2026. doi:10.1093/ibd/izaf333
BibTeX
@article{Dubinsky2026,
author = {Dubinsky, Marla C and Chaparro, María and Irving, Peter M and Hur, Peter and Sidhu, Sarah and Woolcott, John C and Wang, Wenjin and Goetsch, Martina and Torres, Joana and Panaccione, Remo},
title = {Rapid symptomatic improvement with etrasimod in ulcerative colitis: a post-hoc analysis of the ELEVATE UC program},
journal = {Inflammatory Bowel Diseases},
year = {2026},
doi = {10.1093/ibd/izaf333}
}
EUVIMED